IOL Chemicals & Pharmaceuticals Q4 FY26 Results

Net Profit (Q4 FY26): ₹53 crore
Revenue (Q4 FY26): ₹619 crore

Reader Takeaway: Strong profit growth driven by capacity ramp-up; monitor import dependency and capex execution.

What just happened

IOL Chemicals and Pharmaceuticals Limited announced its financial results for the fourth quarter and full year ended March 31, 2026. The company reported a robust 65.6% increase in Profit After Tax (PAT) for Q4 FY26, reaching ₹53 crore compared to ₹32 crore in the same period last year. Revenue from operations grew by 17.2% to ₹619 crore in Q4 FY26 from ₹528 crore in Q4 FY25. For the full fiscal year FY26, PAT stood at ₹138 crore on revenues of ₹2,319 crore.

Why this matters

The strong profit growth indicates improved operational efficiency and margin expansion. The company's forward-looking guidance for FY27, targeting an EBITDA margin of 14% to 14.5%, signals continued profitability improvement. Furthermore, the announcement of a substantial ₹1,200–₹1,400 crore greenfield capex plan signals a long-term growth strategy and potential for increased market share.

The backstory

IOL Chemicals and Pharmaceuticals is a significant player in the pharmaceutical and specialty chemical sectors. The company has been focusing on expanding its product portfolio and manufacturing capacities. In the previous fiscal year, FY25, the company reported PAT of ₹100 crore. The current results show a marked improvement in performance.

What changes now

With enhanced profitability and clear guidance, investor sentiment may improve. The significant greenfield capex plan indicates a strategic shift towards substantial expansion, which could lead to higher volumes and revenue in the coming years. The management's correction of inventory figures suggests improved financial reporting clarity.

Risks to watch

A key concern remains the company's import dependency for key starting materials for Metformin, primarily sourced from China. This exposes the company to potential supply chain disruptions. Additionally, geopolitical risks in West Asia could impact logistics and raw material costs, potentially affecting margins if these costs cannot be passed on to customers.

Peer comparison

While specific peer financial data for the same period is not provided in the filing, IOL Chemicals' performance in Q4 FY26 shows strong growth. Competitors in the API and specialty chemicals space in India include companies like Divi's Laboratories, Laurus Labs, and Aarti Industries. These companies also focus on capacity expansion and cost efficiencies, though their product portfolios and market focus may differ.

Context metrics

• Revenue: Q4 FY26 ₹619 crore vs. Q4 FY25 ₹528 crore (up 17.2%).
• EBITDA: Q4 FY26 ₹94 crore vs. Q4 FY25 ₹68 crore (up 38.2%).
• PAT: Q4 FY26 ₹53 crore vs. Q4 FY25 ₹32 crore (up 65.6%).
• Full Year FY26 Revenue: ₹2,319 crore.
• Full Year FY26 PAT: ₹138 crore.
• Inventory: ₹371 crore as of March 31, 2026.
• Capex: ₹160 crore in FY26.

What to track next

Investors will be keen to track the progress and execution of the ₹1,200–₹1,400 crore greenfield expansion project. Monitoring the company's ability to manage import dependencies and navigate geopolitical risks will also be crucial for sustained profitability and growth. The company's ability to achieve its FY27 EBITDA margin guidance of 14%–14.5% will be a key indicator of future performance.